RSS Feed
YouTube
SoundCloud
Instagram
Twitter
Facebook
Submit Search
Search
Close Menu
Search
Home
Latest Stories
Campus
City
COVID-19
Sports
Arts and Entertainment
Opinion
Multimedia
Wildcat GeoGame
Contact
Donate
The Daily Northwestern
Menu
The Daily Northwestern
COVID-19
Campus
Academic
Administration
Alumni
Campus Safety
Events
Faculty
Student Government
Student Groups
All Stories
City
Arts and Technology
Business
Crime
Education
Politics
Features
Evanston Organizes
Portrait of a Ward
All Stories
Sports
Women’s Basketball
Men’s Basketball
Fencing
Wrestling
Women’s Tennis
Men’s Tennis
Swimming & Diving
Lacrosse
Softball
Baseball
All Stories
Opinion
Columns
Contributors
Cartoons
The Spectrum
Editorials
From the Newsroom
Letters to the Editor
All Stories
FAQ
A&E
The Monthly
June Monthly
May Monthly
April Monthly
March Monthly
Theater
Music
Television and Film
Dance
Visual Arts
Literature
All Stories
Podcasts
NU Declassified
Everything Evanston
The Ripple
Podculture
Sound Source
Defining Safe
Speak Your Mind
Brainstorm
Digital Diaries
All Podcasts
Video
All Videos
In Focus
Donate
About
Advertise
Awards
Classifieds
Contact
Editorial Board
Former Daily Editors
Geogame
Homecoming Honorees
Print Archives
Social Media
Join Us
More
»
In Focus: As Lyrica profits dry up, Northwestern seeks another ‘blockbuster’ drug
April 10, 2016
Close
Close Modal Window
